EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Trends in Inflation-Adjusted Pharmacotherapy Costs and Cardiovascular Risk Factor Management in Type 2 Diabetes: A 26-Year Study from Tertiary Diabetes Cen​​​​tres in Greece ​​​

Georgios Karamanakos, Athanasia Papazafiropoulou, Anastasios Koutsovasilis, Kleomenis Salapatas, Marina Vroucho, Vasiliki Chatzivasiloglou, Konstantinos Manganas, Persefoni Michou, Andriana Konstantelou, Anna Garbi, Nicholaos Tentolouris, Stavros Liatis

Experimental and Clinical Endocrinology & Diabetes · 2026-11-05

DOI: 10.1055/a-2978-1630 ↗
AbstractBibliografische Angaben

Abstract

Abstract We evaluated long-term trends in pharmacotherapy costs and cardiovascular risk factor target achievement among people with type 2 diabetes attending tertiary diabetes centres in Greece. This periodic, multicenter, cross-sectional study analysed data from 4,963 people with type 2 diabetes attending three diabetes centres at specific time points: 1998, 2006, 2012, 2018, and 2024. We compared glycated haemoglobin, systolic blood pressure, low-density lipoprotein cholesterol, and body mass index and the achievement of individual cardiovascular risk factor targets (glycated haemoglobin: < 7%, systolic blood pressure: < 140 mm Hg, and low-density lipoprotein cholesterol: < 100 mg/dL) and all three targets simultaneously. Annual pharmacotherapy costs were compared using inflation-adjusted values. Simultaneous achievement of all three cardiovascular risk factor targets increased from 0.6% in 1998 to 29.1% in 2024. Individual target achievements improved: glycated haemoglobin from 29.4 to 58.6%, systolic blood pressure from 45.3 to 62.5%, and low-density lipoprotein cholesterol from 6.3 to 73.4%. Mean low-density lipoprotein cholesterol showed the greatest reduction from 128.4 to 79.0 mg/dL. Median body mass index increased until 2018 and then declined in 2024. Total pharmacotherapy costs per patient rose from €341 in 1998 to €1,609 in 2024, primarily due to glucose-lowering therapies (€167–€1,257). Over 26 years, people with type 2 diabetes attending tertiary diabetes centres in Greece demonstrated improvements in cardiovascular risk factor target achievement, alongside rising pharmacotherapy costs, primarily driven by glucose-lowering therapies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →